Product nameAnti-SLC37A4 antibody
DescriptionRabbit polyclonal to SLC37A4
Tested applicationsSuitable for: ICC/IF, WB, ELISAmore details
Species reactivityReacts with: Human
Predicted to work with: Mouse, Rat, Rabbit, Horse, Guinea pig, Cow, Cat, Dog, Pig
- Fetal brain lysate.
Storage instructionsShipped at 4°C. Upon delivery aliquot and store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.
Storage bufferPreservative: 0.09% Sodium azide
Constituents: 2% Sucrose, PBS
Concentration information loading...
PurityImmunogen affinity purified
Purification notesab80463 is purified by a peptide affinity chromatography method.
- Pathways and Processes
- Metabolic signaling pathways
- Energy transfer pathways
- Energy Metabolism
Our Abpromise guarantee covers the use of ab80463 in the following tested applications.
The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.
|ICC/IF||Use at an assay dependent concentration.|
|WB||Use a concentration of 1 µg/ml. Detects a band of approximately 46 kDa (predicted molecular weight: 46 kDa). Good results were obtained when blocked with 5% non-fat dry milk in 0.05% PBS-T.|
|ELISA||Use at an assay dependent concentration.
ELISA titre using peptide based assay: 1/312500.
FunctionTransports glucose-6-phosphate from the cytoplasm to the lumen of the endoplasmic reticulum. Forms with glucose-6-phosphatase the complex responsible for glucose production through glycogenolysis and gluconeogenesis. Hence, it plays a central role in homeostatic regulation of blood glucose levels.
Tissue specificityMostly expressed in liver and kidney.
Involvement in diseaseDefects in SLC37A4 are the cause of glycogen storage disease type 1B (GSD1B) [MIM:232220]. GSD1B is a metabolic disorder characterized by impairment of terminal steps of glycogenolysis and gluconeogenesis. GSD1 patients manifest a wide range of clinical symptoms and biochemical abnormalities, including hypoglycemia, severe hepatomegaly due to excessive accumulation of glycogen, kidney enlargement, growth retardation, lactic acidemia, hyperlipidemia, and hyperuricemia. GSD1B patients also present a tendency towards infections associated with neutropenia, relapsing aphthous gingivostomatitis, and inflammatory bowel disease.
Defects in SLC37A4 are the cause of glycogen storage disease type 1C (GSD1C) [MIM:232240].
Defects in SLC37A4 are the cause of glycogen storage disease type 1D (GSD1D) [MIM:232240].
Sequence similaritiesBelongs to the major facilitator superfamily. Organophosphate:Pi antiporter (OPA) (TC 2.A.1.4) family.
Cellular localizationEndoplasmic reticulum membrane.
- Information by UniProt
- G6PT1 antibody
- G6PT1_HUMAN antibody
- G6PT2 antibody
ab80463 staining SLC37A4 in Mouse bone marrow cells by ICC/IF (Immunocytochemistry/immunofluorescence). Cells were fixed with formaldehyde, permeabilized with Triton X-100 0.1% and blocked with 5% serum for 2 hours at 21°C. Samples were incubated with primary antibody (1/100 in PBS + 2% BSA) for 12 hours at 4°C. An Alexa Fluor®488-conjugated Goat anti-rabbit IgG polyclonal (1/500)was used as the secondary antibody.
Anti-SLC37A4 antibody (ab80463) at 1 µg/ml + Fetal brain lysate at 10 µg
HRP conjugated anti-Rabbit IgG at 1/50000 dilution
Predicted band size: 46 kDa
Observed band size: 46 kDa
Additional bands at: 25 kDa. We are unsure as to the identity of these extra bands.
ab80463 has not yet been referenced specifically in any publications.